US2017009211A1PendingUtilityA1
DOWNREGULATION OF miR-7 FOR PROMOTION OF BETA CELL DIFFERENTIATION AND INSULIN PRODUCTION
Est. expiryAug 9, 2031(~5 yrs left)· nominal 20-yr term from priority
C12N 5/0662C12N 5/0667A61P 3/10C12N 5/0668C12N 5/0664C12N 5/0666C12N 5/0663C12N 2310/14C12N 2310/141A61P 43/00C12N 5/0665C12N 15/113C12N 2501/65C12N 2320/11A61K 31/7088A61K 35/39C07K 14/62C12N 5/0676C12N 2310/113
42
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A method of ex-vivo increasing insulin content in beta cells or stem cells is disclosed. The method comprising contacting the beta cells or stem cells with an agent for downregulating an activity or expression of miR-7, thereby increasing the insulin content in the beta cells or stem cells.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated population of cells being genetically modified to downregulate expression of miR-7, wherein said cells secrete insulin.
2 . A pharmaceutical composition comprising the isolated population of cells of claim 1 and a pharmaceutically acceptable carrier or diluent.
3 . The isolated population of cells of claim 1 , wherein said cells comprise an agent which downregulates said expression of miR-7.
4 . The isolated population of cells of claim 3 , wherein said agent is a polynucleotide agent.
5 . The isolated population of cells of claim 4 , wherein said agent is an antagomir.
6 . The isolated population of cells of claim 1 , wherein said cells are beta cells.
7 . The isolated population of cells of claim 6 , wherein said beta cells comprise primary beta cells.Join the waitlist — get patent alerts
Track US2017009211A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.